Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.

In the 9 patients for whom baseline (time zero) and final (after IL-2 at the end of the 4th treatment cycle) blood samples were available, we observed a −20.3% (range −84.0% to +569.7%) reduction in Foxp3+Tregs, which, however, did not reach statistical significance even when the two groups (DCR and PD) were considered separately.

also in 111,027 other papers